This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.
Sanofi is in the midst of a shakedown of its business prompted by a decline in sales of its diabetes blockbuster Lantus (insulin glargine) and the failure of some other products
calorie intake by 500 to 750 per day and continued use of glucose-controlling drugs (metformin, acarbose and in some cases basal insulin) to closely manage blood sugar levels. ... According to lead investigator Hertzel Gerstein, the team chose to use
The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination
Eli Lilly and Boehringer Ingelheim have launched their Basaglar copy at a 15% discount to Lantus (insulin glargine), which is already facing tough competition from other insulin products such as Novo ... We know that starting insulin can be a challenging
In the case of Xultophy, the combination is based on Novo's basal insulin Tresiba (insulin degludec) and market-leading GLP-1 agonist Victoza (liraglutide). ... In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan)
More from news
Approximately 23 fully matching, plus 105 partially matching documents found.
In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...